hydroxychloroquine - for COVID-19 mild to moderate   method abbreviations

Outcome Relative effect 95%CI LoD Trt. better when I2 k (RCT/OBS) Bayesian probability Overall ROB Publication bias Degree of certainty Endpoint importance Published MA

efficacy endpoints 00

deaths 1.33 [0.48, 3.64]< 10%4 studies (4/-)29.1 %highnot evaluable lowcrucial-
clinical improvement 3.43 [1.10, 10.70]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-
clinical worsening 0.55 [0.09, 3.27]< 147%2 studies (2/-)74.5 %highnot evaluable lowimportant-
PCR-negative conversion 0.46 [0.04, 5.75]> 10%1 study (1/-)27.7 %some concernnot evaluable moderateimportant-
radiologic improvement (7-day) 3.43 [1.10, 10.70]> 10%1 study (1/-)98.3 %highnot evaluable lowimportant-

-- safety endpoints 00

adverse events 1.16 [0.46, 2.90]< 10%3 studies (3/-)37.7 %highnot evaluable lownon important-

LoD: level of demonstration ( demonstrated, suggested, inconclusive, safety concerns);
Bayesian probability: Bayesian posterior probability of treatment effect (computed with a noninformative prior); ROB: risk of bias; k: number of studies; published MA: number of published meta-analysis on the same topic; degree of certainty adapted from GRADE. Trt. better when: indicates when the relative treatment effect shows that the studied treatment is better than control.



This meta-analysis covered 1 pathologies: 90 90